How does resistance to Tagrisso (osimertinib) happen?
Tagrisso (osimertinib) targets EGFR-mutant non-small cell lung cancer (NSCLC). Resistance most often develops through new EGFR changes, including additional mutations that reduce how well osimertinib binds, or by switching to other growth pathways that can keep the tumor growing despite EGFR inhibition.
What resistance mutations are most commonly linked to Tagrisso failure?
A well-known resistance mechanism is the emergence of EGFR mutations after treatment. One frequently discussed alteration is EGFR C797S, which can reduce osimertinib activity. Other resistance patterns include EGFR-dependent changes that restore signaling and non-EGFR mechanisms that reactivate downstream growth.
What do doctors typically do when Tagrisso resistance develops?
When resistance is suspected, clinicians commonly:
- Re-biopsy or use liquid biopsy (blood) to look for new resistance alterations.
- Use next-line targeted options if a specific actionable resistance change is found.
- Consider chemotherapy or other regimens when targeted options are not available or the tumor’s biology has shifted.
Can Tagrisso resistance differ by whether you start with metastatic disease or earlier-stage EGFR-mutant NSCLC?
Yes. The biology that drives resistance can differ depending on the original EGFR mutation, prior treatments, and tumor evolution over time. Resistance patterns can be different for people treated first-line versus those treated after other EGFR-directed therapies.
How do resistance patterns affect whether you can use another EGFR drug?
Not all resistance mechanisms are treatable the same way. Some EGFR-related resistance mutations may still leave the cancer partly dependent on EGFR signaling, while others drive “bypass” pathways where another EGFR TKI alone is unlikely to work well. That is why post-resistance testing is often central to choosing the next therapy.
Is there a role for clinical trials in Tagrisso-resistant EGFR-mutant NSCLC?
Often, yes. Many trials test new combinations (for example, adding agents that target bypass pathways or combining EGFR inhibitors with drugs aimed at resistance mechanisms). Trial eligibility usually depends on the resistance findings (mutation status, prior therapies, and disease stage).
Where can I find more details on Tagrisso resistance and new therapies?
DrugPatentWatch.com tracks patent and exclusivity information for drug candidates, which can help you identify newer-generation EGFR inhibitors and next-step treatments being developed in response to resistance. See DrugPatentWatch here: https://www.drugpatentwatch.com/
Sources
- https://www.drugpatentwatch.com/